Zimmer Biomet Q2 EPS Estimate Decreased by Zacks Research

Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) - Investment analysts at Zacks Research cut their Q2 2025 earnings per share (EPS) estimates for Zimmer Biomet in a report issued on Monday, May 26th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will post earnings per share of $1.98 for the quarter, down from their prior forecast of $2.03. The consensus estimate for Zimmer Biomet's current full-year earnings is $8.22 per share. Zacks Research also issued estimates for Zimmer Biomet's Q3 2025 earnings at $1.78 EPS, Q4 2025 earnings at $2.38 EPS, FY2025 earnings at $7.95 EPS, Q2 2026 earnings at $2.10 EPS, Q3 2026 earnings at $2.00 EPS, Q4 2026 earnings at $2.08 EPS and FY2027 earnings at $8.60 EPS.

Several other analysts have also weighed in on the stock. Needham & Company LLC reiterated a "hold" rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Royal Bank of Canada decreased their price objective on Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. Barclays lowered their price objective on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating on the stock in a research note on Monday, February 10th. Raymond James cut their target price on Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. Finally, Stifel Nicolaus set a $115.00 price target on Zimmer Biomet and gave the company a "buy" rating in a research report on Tuesday, May 6th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of "Hold" and a consensus price target of $111.53.

Zimmer Biomet Stock Performance

ZBH traded down $1.22 during trading on Wednesday, reaching $92.12. 3,505,131 shares of the company's stock were exchanged, compared to its average volume of 1,805,125. The company has a market capitalization of $18.23 billion, a P/E ratio of 20.70, a PEG ratio of 1.95 and a beta of 0.78. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The business has a 50 day moving average price of $100.36 and a 200 day moving average price of $104.92. Zimmer Biomet has a fifty-two week low of $89.92 and a fifty-two week high of $116.71.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.04. The company had revenue of $1.91 billion for the quarter, compared to analyst estimates of $1.89 billion. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. Zimmer Biomet's revenue for the quarter was up 1.1% compared to the same quarter last year. During the same quarter last year, the firm earned $1.94 EPS.

Hedge Funds Weigh In On Zimmer Biomet

Several hedge funds have recently added to or reduced their stakes in the company. Stonebridge Financial Group LLC acquired a new position in Zimmer Biomet during the 4th quarter valued at about $25,000. Garde Capital Inc. acquired a new position in Zimmer Biomet in the first quarter valued at approximately $29,000. Washington Trust Advisors Inc. acquired a new position in Zimmer Biomet in the first quarter valued at approximately $30,000. Columbia River Financial Group LLC bought a new position in Zimmer Biomet in the first quarter valued at approximately $30,000. Finally, Menard Financial Group LLC acquired a new stake in Zimmer Biomet during the 4th quarter worth $30,000. Institutional investors own 88.89% of the company's stock.

Insider Transactions at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now directly owns 8,768 shares of the company's stock, valued at approximately $915,379.20. This trade represents a 14.13% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.70% of the stock is owned by company insiders.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Thursday, June 26th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.04%. Zimmer Biomet's dividend payout ratio is presently 21.24%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.